Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
By F. Schröder, J. Hugosson, M. Roobol, T. Tammela, M. Zappa, V. Nelen, M. Kwiatkowski, M. Luján, L. Määttänen, Hans Lilja and 19 more. The Lancet, 2014
1,523 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/2a92031bf7a5fafbde89d8656b4d707c63931ef8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Pulmonary and Respiratory Medicine
- Ewout W. Steyerberg
- B. Van calster
- Andrew J. Vickers
- Michel Bolla
- N. Mottet
- J. Bellmunt
- Hans Lilja
- V. Matveev
Citations in the corpus
- Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators (2018, background): “Screening with PSA results in overdiagnosis of indolent prostate cancer [19].”
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2017, methodology): “Table 3 – Follow-up data from the European Randomised Study of Screening for Prostate Cancer study [14]”
- “A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer” (2019, background): “6-fold and the relative reduction in PCa mortality was 21% at 13 yr of follow-up [3].”
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2020, background): “A Cochrane review suggested that prostate-specific antigen (PSA) screening is associated with an increased diagnosis rate (relative risk [RR]: 1. showed a reduction in PCa mortality in the screening arm (RR: 0.79; 95% CI, 0.69 – 0.91) after a median follow-up of 13 yr [24].”